Parse Biosciences offers an Evercode single-cell sequencing product portfolio (Evercode Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect) plus data analysis tools. Its technology enables large-scale single-cell experiments without custom instrumentation and has been adopted by over 1,000 labs worldwide. Products are available across key international markets, including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea. The company recently opened a 34,000 square foot headquarters and laboratory in Seattle’s South Lake Union district. Parse serves academic, biotech, and pharma customers and is expanding support for large-scale programs such as immune profiling and pooled CRISPR screens. The company reports continued customer demand and is scaling operations to meet that demand while broadening applications of its Evercode platform. Parse Biosciences develops the Evercode Whole Transcriptome product line, which uses a patented combinatorial barcoding technique to improve sample resolution, increase transcript sensitivity, and simplify workflow. Its Evercode Whole Transcriptome Mega kit can profile up to 1,000,000 cells in parallel, while the Mini kit profiles up to 10,000 cells for smaller studies. The company plans to expand the Evercode platform beyond transcriptomics into multi-omic measurements and to broaden its product portfolio later this year. Planned new products and applications include immune profiling (gene expression plus receptor profiling), chromatin profiling, high-throughput CRISPR screens, targeted gene panels, and increased sensitivity in transcript detection. Parse said the Series B raise will support commercialization and product expansion. Financially, the company closed a $41.5M Series B and has raised over $50M to date following a $7M Series A in January 2021. Parse Biosciences (formerly Split Biosciences) provides scalable and flexible single-cell sequencing solutions. Its core product, the Whole Transcriptome Kit, enables researchers to profile up to 100,000 cells in parallel across up to 48 samples while improving data quality, increasing gene detection, and reducing confounding artifacts common in single-cell experiments. The company also supplies a computational pipeline that generates experimental reports, gene-cell count matrices and other processed data that integrate with tools like Seurat and Scanpy. The Whole Transcriptome Kit is already used in 40 labs across the country. Parse raised $7M in a Series A to continue scaling the commercial roll-out of the kit. The company is led by Alex Rosenberg (CEO) and Charlie Roco (CTO).

Total raised

$99M

Funding rounds

4

Latest round

Series C

Latest activity

Dec 2023